- Home
- UROY vs ABSI Comparison
UROY vs ABSI Comparison
Compare UROY & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- ABSI
- Stock Information
- Founded
- UROY 2017
- ABSI 2011
- Country
- UROY Canada
- ABSI United States
- Employees
- UROY N/A
- ABSI N/A
- Industry
- UROY
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- ABSI Health Care
- Exchange
- UROY Nasdaq
- ABSI Nasdaq
- Market Cap
- UROY 336.8M
- ABSI 338.0M
- IPO Year
- UROY N/A
- ABSI 2021
- Fundamental
- Price
- UROY $3.15
- ABSI $2.39
- Analyst Decision
- UROY Strong Buy
- ABSI Strong Buy
- Analyst Count
- UROY 2
- ABSI 5
- Target Price
- UROY $4.00
- ABSI $7.98
- AVG Volume (30 Days)
- UROY 2.6M
- ABSI 4.4M
- Earning Date
- UROY 07-16-2025
- ABSI 08-12-2025
- Dividend Yield
- UROY N/A
- ABSI N/A
- EPS Growth
- UROY N/A
- ABSI N/A
- EPS
- UROY N/A
- ABSI N/A
- Revenue
- UROY $11,285,840.00
- ABSI $4,138,000.00
- Revenue This Year
- UROY $228.36
- ABSI $44.71
- Revenue Next Year
- UROY N/A
- ABSI $374.26
- P/E Ratio
- UROY N/A
- ABSI N/A
- Revenue Growth
- UROY N/A
- ABSI 27.32
- 52 Week Low
- UROY $1.43
- ABSI $2.01
- 52 Week High
- UROY $3.30
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- UROY 65.88
- ABSI 33.33
- Support Level
- UROY $2.51
- ABSI $2.50
- Resistance Level
- UROY $2.87
- ABSI $2.73
- Average True Range (ATR)
- UROY 0.16
- ABSI 0.18
- MACD
- UROY 0.05
- ABSI -0.04
- Stochastic Oscillator
- UROY 82.05
- ABSI 1.94
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.